Neurological «masks» of multiple myeloma. Literature review and clinical case
https://doi.org/10.25694/URMJ.2018.11.32
Abstract
The article provides an overview of recent scientific publications on the problem of damage to the nervous system in multiple myeloma. In half of the patients, myeloma is debuted with persistent pain syndrome associated with destructive lesion of the flat bones and compression of the roots and spinal cord. In 20% of cases, polyneuropathy develops as a manifestation of the underlying disease, as well as a complication of chemotherapy used to treat myeloma. Involvement of the nervous system is always secondary, but usually develops before the clinic of the main hematological disease or symptoms of damage to the nervous system muffle the clinic of multiple myeloma. There is a need for diagnostic alertness of specialists regarding oncohematological pathology. After chemotherapy, most patients need advice from neurologists in connection with polyneuropathy developing on this background. Over the past decades, the mechanisms of damage and the pathogenesis of polyneuropathy on the background of tumor blood diseases, which are presented in the article, have been described. The same is a clinical case of myeloma, manifested by neurological symptoms.
About the Authors
E. S. Shishkina
ФГБОУ ВО «Кировский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
T. V. Baidina
ФГБОУ ВО «Пермский государственный медицинский университет им. академика Е.А. Вагнера» Минздрава России
Russian Federation
Russian Federation
E. S. Fokina
ФГБУН КНИИГиПК ФМБА России
Russian Federation
Russian Federation
N. V. Minaeva
ФГБУН КНИИГиПК ФМБА России
Russian Federation
Russian Federation
References
1. Hajek R., Krejci M., Pour L., Adam Z. Multiple myeloma. Klin. Onkol. 2011; 24: 11-3.
2. Вотякова О.М., Демина Е.А. Множественная миелома. Клиническая онкогематология. Волкова М.А. ред. М.: Медицина; 2001.
3. Blade J., Kyle R.A. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk. Lymphoma. 1998; 30: 493-501.
4. Гинзберг М.А. Демиелинизирующие полиневропатии, ассоциированные с парапротеинемией (клинико-электрофизиологическое и иммунологическое исследование): Автореф. дисс.. канд. мед. наук: М.; 2015.
5. Oshima K., Kanda Y., Nannya Y., Kaleko M., Hamaki T., Suguro M. et al. Clinical and pathologic fingings in 52 consecutively autopsied cases with multiple myeloma. American Journal of Hematology. 2001; 67(1): 1-5.
6. Niscola P., Scaramucci L., Romani C., Giovannini M., Tendas A., Brunetty G. et al. Pain management in multiple myeloma. Expert Review of Anticancer Therapy. 2010; 10 (3): 415-25.
7. Richardson P.G., Delforge M., Beksac M. et al. Management of treatment-emergent peripherical neuropathy in multiple myeloma. Leukemia. 2012; 26: 595-608.
8. Бессмельцев С.С. Множественная миелома. Вестник гематологии. 2014: 10(3): 6-15.
9. Меркулова Д.М., Чернова П.А., Меркулов Ю.А., Калашников А.А., Щербенкова А.А. Патофизиологические механизмы формирования полинейропатии при парапротеинемии. Патогенез. 2008; 6(4): 45-48.
10. Hajek R., Krejci M., Pour L., Adam Z. Multiple myeloma. Klin. Oncol. 2011; 24: 11-3.
11. Becker P.S. Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma. Klin. Oncol. 2011; 29(7): 783-6.
12. Na J.H., Park S.H., Shin S.Y. Multiple myeloma manifesting as actuating sixth nerve palsy. Korean J. Ophtalmol. 2009; 23(3): 232-3.
13. Simmons Z. Paraproteinemia and neuropathy. Curr. Opin. Neurol. 1999; 12(5): 589-95.
14. Willison H.J., Yuki N. Peripheral neuropathies and antiglycolipid antibodies. Brain. 2002; 125(12): 2591625.
15. Kelly J.J. The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. Muscle Nerve. 1983; 6: 504-9.
16. Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematiol. 2011; 32: 45-59.
17. Vermeiren P., Vantilborgh A., Offner F. Myeloma of the central nervous system: report of a single center case series. Acta Clin. Belg. 2011; 66(3): 205-8.
18. Ковражкина Е.А. Аксональные полинейропатии: патогенез и лечение. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013; 6: 22-5.
19. Bhagra A., Rao R.D. Chemotherapy-induced neuropathy. Curr. Oncol. Rep. 2007; 9(4): 290-9.
20. Wolf S., Barton D., Kottschade L. et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008; 44 (11): 1507-15.
21. Ватутин Н.Т., Склянная Е.В., Эль-Хатиб М.А., Макарова М.В., Старченко С.В. Периферические полинейропатии, индуцированные различными химиотерапевтическими агентами: современное состояние проблемы. Гематология и трансфузиология. 2016; 61(2): 105-9.
22. Cavaletti G., Bogliun G., Marzorati L., Zincone A., Piatti M., Colombo N. et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann. Oncol. 2004; 15(9): 1439-42.
23. Griswold W., Oberndorfer S., Windebank A.J. Chemotherapy and polyneuropathies. Eur Assoc Neurol Mag 2012; 2 (1): 25-36.
24. Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubulestabilizing agents. J. Clin. Oncol. 2006; 24(10): 1633-42.
25. Smith E.M., Pang h., Cirrincione C., Fleishman S., Paskett E.D., Ahles T. et al. Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trail. JAMA. 2013; 309(13): 1359-67. DOI: 10.1001/jama.2013.2813.
26. Haan J., Peters W.G. Amyloid and peripheral nervous system disease. Clin. Neurol. Neurosurg. 1994; 96(1): 1-9.
27. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders. Br. J. Haematol. 2003; 121: 749-57.
Review
For citations:
Shishkina ES, Baidina TV, Fokina ES, Minaeva NV. Neurological «masks» of multiple myeloma. Literature review and clinical case. Ural Medical Journal. 2018;(11):94-99. (In Russ.) https://doi.org/10.25694/URMJ.2018.11.32
Views:
175
Email this article 